Camlin Fine Sciences Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: May 24, 2025, 1:49 pm

Market Cap	3,531 Cr.
Current Price	188
High / Low	205/78.1
Stock P/E	79.0
Book Value	48.0
Dividend Yield	0.00 %
ROCE	10.3 %
ROE	5.06 %
Face Value	1.00
PEG Ratio	-1.86

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Camlin Fine Sciences Ltd

Competitors of Camlin Fine Sciences Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
HP Adhesives Ltd	480 Cr.	52.3	108/42.6	26.9	20.0	0.57 %	13.9 %	10.1 %	2.00
Haryana Leather Chemicals Ltd	37.2 Cr.	75.8	124/62.6	16.2	87.4	1.32 %	8.04 %	5.47 %	10.0
Hardcastle & Waud Mfg Co Ltd	52.1 Cr.	766	1,355/600	29.8	663	0.00 %	7.00 %	5.98 %	10.0
Grauer & Weil (India) Ltd	3,773 Cr.	83.2	120/72.2	23.5	19.2	0.60 %	26.1 %	19.6 %	1.00
DMCC Speciality Chemicals Ltd	654 Cr.	262	453/241	30.4	91.1	0.38 %	14.6 %	9.87 %	10.0
Industry Average	12,808.73 Cr	810.06		50.17	180.71	0.38%	13.15%	9.86%	6.44

All Competitor Stocks of Camlin Fine Sciences Ltd

Quarterly Result

Metric	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Sales	380.82	389.23	383.77	483.25	387.84	426.71	419.60	405.88	385.89	401.69	395.85	422.97	433.49
Expenses	325.65	364.90	337.15	428.04	338.08	382.89	380.89	380.74	362.56	414.94	377.72	379.73	386.56
Operating Profit	55.17	24.33	46.62	55.21	49.76	43.82	38.71	25.14	23.33	-13.25	18.13	43.24	46.93
OPM %	14.49%	6.25%	12.15%	11.42%	12.83%	10.27%	9.23%	6.19%	6.05%	-3.30%	4.58%	10.22%	10.83%
Other Income	5.58	21.35	1.03	2.88	9.76	-7.68	6.37	1.76	1.66	-44.04	1.87	-138.44	1.34
Interest	6.82	9.76	18.73	18.45	11.55	9.78	10.22	19.78	14.14	16.17	23.37	26.42	34.12
Depreciation	13.24	15.94	14.37	14.02	16.18	17.93	18.78	19.20	20.58	20.05	20.11	20.69	14.48
Profit before tax	40.69	19.98	14.55	25.62	31.79	8.43	16.08	-12.08	-9.73	-93.51	-23.48	-142.31	-0.33
Tax %	33.28%	33.28%	75.26%	61.44%	28.09%	58.72%	25.25%	72.43%	46.66%	-12.53%	47.57%	-18.41%	2,163.64%
Net Profit	27.15	13.33	3.60	9.87	22.86	3.48	12.01	-20.83	-14.28	-81.79	-34.65	-116.11	-7.48
EPS in Rs	2.01	0.86	0.33	0.74	1.36	0.52	0.83	-1.03	-0.63	-4.11	-1.81	-5.33	-0.22

Last Updated: March 3, 2025, 5:06 pm

Below is a detailed analysis of the quarterly data for Camlin Fine Sciences Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

For Sales, as of Dec 2024, the value is 433.49 Cr.. The value appears strong and on an upward trend. It has increased from 422.97 Cr. (Sep 2024) to 433.49 Cr., marking an increase of 10.52 Cr..
For Expenses, as of Dec 2024, the value is 386.56 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 379.73 Cr. (Sep 2024) to 386.56 Cr., marking an increase of 6.83 Cr..
For Operating Profit, as of Dec 2024, the value is 46.93 Cr.. The value appears strong and on an upward trend. It has increased from 43.24 Cr. (Sep 2024) to 46.93 Cr., marking an increase of 3.69 Cr..
For OPM %, as of Dec 2024, the value is 10.83%. The value appears strong and on an upward trend. It has increased from 10.22% (Sep 2024) to 10.83%, marking an increase of 0.61%.
For Other Income, as of Dec 2024, the value is 1.34 Cr.. The value appears strong and on an upward trend. It has increased from -138.44 Cr. (Sep 2024) to 1.34 Cr., marking an increase of 139.78 Cr..
For Interest, as of Dec 2024, the value is 34.12 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 26.42 Cr. (Sep 2024) to 34.12 Cr., marking an increase of 7.70 Cr..
For Depreciation, as of Dec 2024, the value is 14.48 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 20.69 Cr. (Sep 2024) to 14.48 Cr., marking a decrease of 6.21 Cr..
For Profit before tax, as of Dec 2024, the value is -0.33 Cr.. The value appears strong and on an upward trend. It has increased from -142.31 Cr. (Sep 2024) to -0.33 Cr., marking an increase of 141.98 Cr..
For Tax %, as of Dec 2024, the value is 2,163.64%. The value appears to be increasing, which may not be favorable. It has increased from -18.41% (Sep 2024) to 2,163.64%, marking an increase of 2,182.05%.
For Net Profit, as of Dec 2024, the value is -7.48 Cr.. The value appears strong and on an upward trend. It has increased from -116.11 Cr. (Sep 2024) to -7.48 Cr., marking an increase of 108.63 Cr..
For EPS in Rs, as of Dec 2024, the value is -0.22. The value appears strong and on an upward trend. It has increased from -5.33 (Sep 2024) to -0.22, marking an increase of 5.11.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 4:38 pm

Metric	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	374	509	558	489	534	721	892	1,049	1,187	1,412	1,682	1,613	1,654
Expenses	327	446	474	397	502	705	819	914	1,000	1,254	1,468	1,529	1,559
Operating Profit	47	63	84	92	32	16	73	135	187	158	213	84	95
OPM %	13%	12%	15%	19%	6%	2%	8%	13%	16%	11%	13%	5%	6%
Other Income	10	9	9	-1	14	12	14	3	5	33	-4	-34	-179
Interest	20	25	24	24	31	32	41	48	42	41	66	70	100
Depreciation	14	12	16	17	22	27	29	33	44	56	63	79	75
Profit before tax	24	35	53	50	-6	-31	17	58	105	94	80	-99	-260
Tax %	36%	18%	-4%	28%	-26%	-22%	82%	49%	38%	36%	50%	6%
Net Profit	15	29	55	36	-4	-24	3	30	65	60	40	-105	-240
EPS in Rs	1.43	2.71	5.11	3.30	-0.96	-2.18	0.04	2.23	3.56	3.45	2.96	-4.94	-11.47
Dividend Payout %	19%	12%	8%	12%	0%	0%	0%	0%	0%	0%	0%	0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2013-2014	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	93.33%	89.66%	-34.55%	-111.11%	-500.00%	112.50%	900.00%	116.67%	-7.69%	-33.33%	-362.50%
Change in YoY Net Profit Growth (%)	0.00%	-3.68%	-124.20%	-76.57%	-388.89%	612.50%	787.50%	-783.33%	-124.36%	-25.64%	-329.17%

Camlin Fine Sciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:	12%
5 Years:	10%
3 Years:	6%
TTM:	3%

Compounded Profit Growth
10 Years:	-2%
5 Years:	8%
3 Years:	-10%
TTM:	175%

Stock Price CAGR
10 Years:	7%
5 Years:	40%
3 Years:	18%
1 Year:	94%

Return on Equity
10 Years:	4%
5 Years:	4%
3 Years:	1%
Last Year:	5%

Last Updated: Unknown

Balance Sheet

Last Updated: December 14, 2024, 3:51 pm

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	9	9	10	10	10	12	12	12	13	16	16	17	17
Reserves	56	84	125	167	202	359	359	391	631	732	804	848	673
Borrowings	126	150	160	180	331	373	461	539	550	646	801	683	767
Other Liabilities	178	126	131	123	126	273	255	290	282	396	425	424	429
Total Liabilities	369	369	426	479	669	1,016	1,087	1,232	1,475	1,790	2,045	1,972	1,885
Fixed Assets	83	83	106	140	201	278	272	306	584	601	858	816	721
CWIP	1	22	3	25	8	14	59	179	24	215	43	46	22
Investments	1	1	1	1	19	115	11	7	7	7	8	8	23
Other Assets	284	262	316	313	442	609	745	740	861	966	1,136	1,102	1,119
Total Assets	369	369	426	479	669	1,016	1,087	1,232	1,475	1,790	2,045	1,972	1,885

Below is a detailed analysis of the balance sheet data for Camlin Fine Sciences Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

For Equity Capital, as of Sep 2024, the value is 17.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 17.00 Cr..
For Reserves, as of Sep 2024, the value is 673.00 Cr.. The value appears to be declining and may need further review. It has decreased from 848.00 Cr. (Mar 2024) to 673.00 Cr., marking a decrease of 175.00 Cr..
For Borrowings, as of Sep 2024, the value is 767.00 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 683.00 Cr. (Mar 2024) to 767.00 Cr., marking an increase of 84.00 Cr..
For Other Liabilities, as of Sep 2024, the value is 429.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 424.00 Cr. (Mar 2024) to 429.00 Cr., marking an increase of 5.00 Cr..
For Total Liabilities, as of Sep 2024, the value is 1,885.00 Cr.. The value appears to be improving (decreasing). It has decreased from 1,972.00 Cr. (Mar 2024) to 1,885.00 Cr., marking a decrease of 87.00 Cr..
For Fixed Assets, as of Sep 2024, the value is 721.00 Cr.. The value appears to be declining and may need further review. It has decreased from 816.00 Cr. (Mar 2024) to 721.00 Cr., marking a decrease of 95.00 Cr..
For CWIP, as of Sep 2024, the value is 22.00 Cr.. The value appears to be declining and may need further review. It has decreased from 46.00 Cr. (Mar 2024) to 22.00 Cr., marking a decrease of 24.00 Cr..
For Investments, as of Sep 2024, the value is 23.00 Cr.. The value appears strong and on an upward trend. It has increased from 8.00 Cr. (Mar 2024) to 23.00 Cr., marking an increase of 15.00 Cr..
For Other Assets, as of Sep 2024, the value is 1,119.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,102.00 Cr. (Mar 2024) to 1,119.00 Cr., marking an increase of 17.00 Cr..
For Total Assets, as of Sep 2024, the value is 1,885.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,972.00 Cr. (Mar 2024) to 1,885.00 Cr., marking a decrease of 87.00 Cr..

However, the Borrowings (767.00 Cr.) are higher than the Reserves (₹673.00 Cr.), which may signal higher financial risk.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity +	27	46	72	-9	-15	-9	86	117	145	51	139	27
Cash from Investing Activity +	-32	-26	-66	-70	-149	-2	-90	-133	-249	-125	-66	-75
Cash from Financing Activity +	-6	-15	-7	91	182	26	3	39	136	60	-86	72
Net Cash Flow	-12	4	-1	13	18	15	-1	23	32	-14	-13	24

Free Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	-79.00	-87.00	-76.00	-88.00	-299.00	-357.00	-388.00	-404.00	-363.00	-488.00	-588.00	-599.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	85	73	74	56	99	104	86	88	83	77	66	65
Inventory Days	330	145	184	311	277	207	219	204	200	178	255	216
Days Payable	349	132	144	171	110	154	127	119	99	112	129	130
Cash Conversion Cycle	66	85	114	196	266	157	178	173	184	143	192	151
Working Capital Days	72	71	91	109	178	144	143	120	123	103	125	121
ROCE %	24%	28%	28%	24%	5%	0%	7%	11%	13%	10%	10%	1%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Jan 2025
Promoters	17.65%	17.64%	17.64%	17.64%	16.52%	48.03%	48.03%	48.04%	48.03%	48.03%	48.03%	49.09%
FIIs	10.74%	11.32%	10.94%	10.18%	10.11%	1.61%	0.99%	1.69%	1.01%	0.81%	0.76%	0.82%
DIIs	14.20%	13.53%	12.53%	12.32%	9.31%	3.89%	3.75%	4.55%	4.88%	4.23%	3.38%	4.09%
Government	0.00%	0.00%	0.00%	0.03%	0.03%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Public	57.42%	57.52%	58.88%	59.82%	64.01%	46.46%	47.22%	45.73%	46.07%	46.93%	47.83%	45.98%
No. of Shareholders	57,835	57,904	54,197	52,921	52,278	57,098	62,098	58,165	62,687	67,750	61,893	60,554

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
ICICI Prudential Smallcap Fund	4,283,136	1.16	70.22	4,283,136	2025-04-22 17:25:39	0%
HSBC Small Cap Equity Fund - OLD	400,000	2.09	6.28	400,000	2025-04-22 17:25:39	0%
ICICI Prudential Dividend Yield Equity Fund	224,082	0.15	3.67	224,082	2025-04-22 17:25:39	0%
Motilal Oswal Nifty Microcap 250 Index Fund	82,017	0.35	1.34	82,017	2025-04-22 17:25:39	0%

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	1.00	1.00	1.00	1.00	1.00
Basic EPS (Rs.)	-5.58	3.45	4.65	4.13	2.50
Diluted EPS (Rs.)	-5.50	3.41	4.56	3.68	2.50
Cash EPS (Rs.)	-1.57	6.51	7.42	8.60	5.17
Book Value[Excl.RevalReserv]/Share (Rs.)	48.29	48.18	43.26	47.81	37.67
Book Value[Incl.RevalReserv]/Share (Rs.)	50.97	52.25	48.52	55.67	37.67
Revenue From Operations / Share (Rs.)	96.32	107.04	89.95	93.11	86.52
PBDIT / Share (Rs.)	5.34	13.44	11.84	14.66	11.06
PBIT / Share (Rs.)	0.64	9.46	8.27	11.19	8.36
PBT / Share (Rs.)	-5.93	5.12	5.99	8.24	4.80
Net Profit / Share (Rs.)	-6.26	2.53	3.85	5.13	2.46
NP After MI And SOA / Share (Rs.)	-5.54	3.32	3.87	4.00	2.50
PBDIT Margin (%)	5.54	12.55	13.16	15.74	12.78
PBIT Margin (%)	0.67	8.83	9.19	12.01	9.65
PBT Margin (%)	-6.15	4.77	6.66	8.85	5.54
Net Profit Margin (%)	-6.50	2.36	4.28	5.50	2.84
NP After MI And SOA Margin (%)	-5.75	3.09	4.29	4.29	2.88
Return on Networth / Equity (%)	-11.35	6.92	9.16	9.43	7.58
Return on Capital Employeed (%)	0.89	11.72	10.77	14.20	14.76
Return On Assets (%)	-4.75	2.52	3.37	3.43	2.45
Long Term Debt / Equity (X)	0.40	0.54	0.58	0.50	0.52
Total Debt / Equity (X)	0.80	1.04	0.94	0.99	1.22
Asset Turnover Ratio (%)	0.80	0.46	0.48	0.52	0.58
Current Ratio (X)	1.37	1.37	1.50	1.66	1.23
Quick Ratio (X)	0.66	0.65	0.87	0.99	0.68
Inventory Turnover Ratio (X)	1.38	1.29	1.65	1.79	1.97
Interest Coverage Ratio (X)	1.48	3.61	5.20	4.98	3.11
Interest Coverage Ratio (Post Tax) (X)	0.08	1.85	2.69	2.74	1.69
Enterprise Value (Cr.)	2050.95	2685.65	2687.50	2251.73	959.50
EV / Net Operating Revenue (X)	1.27	1.60	1.90	1.90	0.91
EV / EBITDA (X)	22.92	12.72	14.46	12.05	7.15
MarketCap / Net Operating Revenue (X)	0.92	1.19	1.55	1.50	0.45
Price / BV (X)	1.83	2.66	3.31	3.30	1.19
Price / Net Operating Revenue (X)	0.92	1.19	1.55	1.50	0.45
EarningsYield	-0.06	0.02	0.02	0.02	0.06

After reviewing the key financial ratios for Camlin Fine Sciences Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 24, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 1.00.
For Basic EPS (Rs.), as of Mar 24, the value is -5.58. This value is below the healthy minimum of 5. It has decreased from 3.45 (Mar 23) to -5.58, marking a decrease of 9.03.
For Diluted EPS (Rs.), as of Mar 24, the value is -5.50. This value is below the healthy minimum of 5. It has decreased from 3.41 (Mar 23) to -5.50, marking a decrease of 8.91.
For Cash EPS (Rs.), as of Mar 24, the value is -1.57. This value is below the healthy minimum of 3. It has decreased from 6.51 (Mar 23) to -1.57, marking a decrease of 8.08.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 48.29. It has increased from 48.18 (Mar 23) to 48.29, marking an increase of 0.11.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 50.97. It has decreased from 52.25 (Mar 23) to 50.97, marking a decrease of 1.28.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 96.32. It has decreased from 107.04 (Mar 23) to 96.32, marking a decrease of 10.72.
For PBDIT / Share (Rs.), as of Mar 24, the value is 5.34. This value is within the healthy range. It has decreased from 13.44 (Mar 23) to 5.34, marking a decrease of 8.10.
For PBIT / Share (Rs.), as of Mar 24, the value is 0.64. This value is within the healthy range. It has decreased from 9.46 (Mar 23) to 0.64, marking a decrease of 8.82.
For PBT / Share (Rs.), as of Mar 24, the value is -5.93. This value is below the healthy minimum of 0. It has decreased from 5.12 (Mar 23) to -5.93, marking a decrease of 11.05.
For Net Profit / Share (Rs.), as of Mar 24, the value is -6.26. This value is below the healthy minimum of 2. It has decreased from 2.53 (Mar 23) to -6.26, marking a decrease of 8.79.
For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is -5.54. This value is below the healthy minimum of 2. It has decreased from 3.32 (Mar 23) to -5.54, marking a decrease of 8.86.
For PBDIT Margin (%), as of Mar 24, the value is 5.54. This value is below the healthy minimum of 10. It has decreased from 12.55 (Mar 23) to 5.54, marking a decrease of 7.01.
For PBIT Margin (%), as of Mar 24, the value is 0.67. This value is below the healthy minimum of 10. It has decreased from 8.83 (Mar 23) to 0.67, marking a decrease of 8.16.
For PBT Margin (%), as of Mar 24, the value is -6.15. This value is below the healthy minimum of 10. It has decreased from 4.77 (Mar 23) to -6.15, marking a decrease of 10.92.
For Net Profit Margin (%), as of Mar 24, the value is -6.50. This value is below the healthy minimum of 5. It has decreased from 2.36 (Mar 23) to -6.50, marking a decrease of 8.86.
For NP After MI And SOA Margin (%), as of Mar 24, the value is -5.75. This value is below the healthy minimum of 8. It has decreased from 3.09 (Mar 23) to -5.75, marking a decrease of 8.84.
For Return on Networth / Equity (%), as of Mar 24, the value is -11.35. This value is below the healthy minimum of 15. It has decreased from 6.92 (Mar 23) to -11.35, marking a decrease of 18.27.
For Return on Capital Employeed (%), as of Mar 24, the value is 0.89. This value is below the healthy minimum of 10. It has decreased from 11.72 (Mar 23) to 0.89, marking a decrease of 10.83.
For Return On Assets (%), as of Mar 24, the value is -4.75. This value is below the healthy minimum of 5. It has decreased from 2.52 (Mar 23) to -4.75, marking a decrease of 7.27.
For Long Term Debt / Equity (X), as of Mar 24, the value is 0.40. This value is within the healthy range. It has decreased from 0.54 (Mar 23) to 0.40, marking a decrease of 0.14.
For Total Debt / Equity (X), as of Mar 24, the value is 0.80. This value is within the healthy range. It has decreased from 1.04 (Mar 23) to 0.80, marking a decrease of 0.24.
For Asset Turnover Ratio (%), as of Mar 24, the value is 0.80. It has increased from 0.46 (Mar 23) to 0.80, marking an increase of 0.34.
For Current Ratio (X), as of Mar 24, the value is 1.37. This value is below the healthy minimum of 1.5. There is no change compared to the previous period (Mar 23) which recorded 1.37.
For Quick Ratio (X), as of Mar 24, the value is 0.66. This value is below the healthy minimum of 1. It has increased from 0.65 (Mar 23) to 0.66, marking an increase of 0.01.
For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.38. This value is below the healthy minimum of 4. It has increased from 1.29 (Mar 23) to 1.38, marking an increase of 0.09.
For Interest Coverage Ratio (X), as of Mar 24, the value is 1.48. This value is below the healthy minimum of 3. It has decreased from 3.61 (Mar 23) to 1.48, marking a decrease of 2.13.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 0.08. This value is below the healthy minimum of 3. It has decreased from 1.85 (Mar 23) to 0.08, marking a decrease of 1.77.
For Enterprise Value (Cr.), as of Mar 24, the value is 2,050.95. It has decreased from 2,685.65 (Mar 23) to 2,050.95, marking a decrease of 634.70.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 1.27. This value is within the healthy range. It has decreased from 1.60 (Mar 23) to 1.27, marking a decrease of 0.33.
For EV / EBITDA (X), as of Mar 24, the value is 22.92. This value exceeds the healthy maximum of 15. It has increased from 12.72 (Mar 23) to 22.92, marking an increase of 10.20.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 0.92. This value is below the healthy minimum of 1. It has decreased from 1.19 (Mar 23) to 0.92, marking a decrease of 0.27.
For Price / BV (X), as of Mar 24, the value is 1.83. This value is within the healthy range. It has decreased from 2.66 (Mar 23) to 1.83, marking a decrease of 0.83.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 0.92. This value is below the healthy minimum of 1. It has decreased from 1.19 (Mar 23) to 0.92, marking a decrease of 0.27.
For EarningsYield, as of Mar 24, the value is -0.06. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 23) to -0.06, marking a decrease of 0.08.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Camlin Fine Sciences Ltd as of May 24, 2025 is: 156.57

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of May 24, 2025, Camlin Fine Sciences Ltd is Overvalued by 16.72% compared to the current share price 188.00

Intrinsic Value of Camlin Fine Sciences Ltd as of May 24, 2025 is: 89.89

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of May 24, 2025, Camlin Fine Sciences Ltd is Overvalued by 52.19% compared to the current share price 188.00

Last 5 Year EPS CAGR: -42.59%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The company has shown consistent growth in sales (314.08 cr) and profit (9.23 cr) over the years.	The stock has a low average ROCE of 13.42%, which may not be favorable. The stock has a high average Working Capital Days of 116.67, which may not be favorable. The stock has a high average Cash Conversion Cycle of 158.75, which may not be favorable. The company has higher borrowings (443.62) compared to reserves (417.77), which may suggest financial risk.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Camlin Fine Sciences Ltd:
1. Net Profit Margin: -6.5%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 0.89% (Industry Average ROCE: 13.15%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: -11.35% (Industry Average ROE: 9.55%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 0.08
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 0.66
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 79 (Industry average Stock P/E: 43.9)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.8
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Camlin Fine Sciences Ltd. is a Public Limited Listed company incorporated on 30/11/1993 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L74100MH1993PLC075361 and registration number is 075361. Currently Company is involved in the business activities of Manufacture of organic and inorganic chemical compounds. Company's Total Operating Revenue is Rs. 773.26 Cr. and Equity Capital is Rs. 16.75 Cr. for the Year ended 31/03/2024.

INDUSTRY	ADDRESS	CONTACT
Chemicals - Speciality - Others	Floor 2 to 5, In GS Point, CST Road, Kalina, Mumbai Maharashtra 400098	secretarial@camlinfs.com https://www.camlinfs.com

Management
Name	Position Held
Mr. Ashish Dandekar	Chairman & Managing Director
Mr. Nirmal Momaya	Managing Director
Mr. Arjun Dukane	Executive Director -Technical
Mr. Mahabaleshwar Palekar	Independent Director
Mr. Pradip Kanakia	Independent Director
Mr. Amol Shah	Independent Director
Mr. Sutapa Banerjee	Independent Director
Mr. Joseph Conrad D'souza	Independent Director
Ms. Anagha Dandekar	Non Exe.Non Ind.Director
Mr. Harsha Raghavan	Non Exe.Non Ind.Director

FAQ

What is the intrinsic value of Camlin Fine Sciences Ltd?

Camlin Fine Sciences Ltd's intrinsic value (as of 24 May 2025) is ₹156.57 — 16.72% lower the current market price of 188.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 3,531 Cr. market cap, FY2025-2026 high/low of ₹205/78.1, reserves of 673 Cr, and liabilities of 1,885 Cr.

What is the Market Cap of Camlin Fine Sciences Ltd?

The Market Cap of Camlin Fine Sciences Ltd is 3,531 Cr..

What is the current Stock Price of Camlin Fine Sciences Ltd as on 24 May 2025?

The current stock price of Camlin Fine Sciences Ltd as on 24 May 2025 is 188.

What is the High / Low of Camlin Fine Sciences Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Camlin Fine Sciences Ltd stocks is ₹205/78.1.

What is the Stock P/E of Camlin Fine Sciences Ltd?

The Stock P/E of Camlin Fine Sciences Ltd is 79.0.

What is the Book Value of Camlin Fine Sciences Ltd?

The Book Value of Camlin Fine Sciences Ltd is 48.0.

What is the Dividend Yield of Camlin Fine Sciences Ltd?

The Dividend Yield of Camlin Fine Sciences Ltd is 0.00 %.

What is the ROCE of Camlin Fine Sciences Ltd?

The ROCE of Camlin Fine Sciences Ltd is 10.3 %.

What is the ROE of Camlin Fine Sciences Ltd?

The ROE of Camlin Fine Sciences Ltd is 5.06 %.

What is the Face Value of Camlin Fine Sciences Ltd?

The Face Value of Camlin Fine Sciences Ltd is 1.00.